c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity.The mature receptor is made up of the alpha and beta subunits, which are disulfide linked after post-translational cleavage of the primary single chain precursor protein. A membrane receptor called c-Met is crucial for both wound healing and embryonic development. The c-Met receptor's sole known ligand is hepatocyte growth factor (HGF). Cells of epithelial origin typically express c-Met, whereas cells of mesenchymal origin only express HGF. In response to HGF stimulation, c-Met triggers a number of biological processes that together give rise to the invasive growth program.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2201 | Capmatinib HCl hydrate (INCB-28060; INC280) | 1865733-40-9 | CapmatinibHCl hydrate (INCB28060; INC-280) is a n FDA-approved, orally bioavailable, ATP-competitive inhibitor of c-MET (IC50 = 0.13 nM in a cell-free assay) with anticancer activity. |
|
V69298 | Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) | 2757108-69-1 | Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a bioactive peptide that reverses deleterious changes associated with aging in multiple organs. |
|
V2760 | CEP-40783 (RXDX-106) | 1437321-24-8 | RXDX-106 (also known as CEP-40783) is an orally bioavailable, nanomolar potent and highly kinase-selective Type II inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. |
|
V0590 | Crizotinib (Xalkori; PF02341066) | 877399-52-5 | Crizotinib (formerly known as PF-02341066; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK with potential anticancer activity. |
|
V78322 | D6808 | D6808 is a selective c-Met inhibitor (antagonist) with IC50 of 2.9 nM. | |
|
V69314 | Davutamig (REGN-5093) | 2648058-48-2 | Davutamig (REGN-5093) is a humanized immunoglobulin G4-kappa, anti-MET monoclonal antibody (mAb) that targets two distinct, non-overlapping epitopes on MET. |
|
V69300 | Emibetuzumab (LY2875358) | 1365287-97-3 | Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). |
|
V69309 | Emzeltrectinib | 2223678-97-3 | Emzeltrectinib is a potent tyrosine kinase inhibitor (TKI) (antagonist) with anti-tumor effects. |
|
V69304 | Ficlatuzumab | 1174900-84-5 | Ficlatuzumab is a monoclonal antibody (mAb) (McAb) targeting human hepatocyte growth factor (HGF). |
|
V69302 | Fosgonimeton (ATH-1017) | 2093305-05-4 | Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor agonist (activator) (WO2017210489). |
|
V69307 | Gemnelatinib | 2225123-30-6 | Gemnelatinib is a tyrosine kinase inhibitor (TKI) (WO2018077227, Example 1). |
|
V5225 | Glumetinib (SCC244) | 1642581-63-2 | Glumetinib (SCC244; SCC-244; Gumarontinib) is a novel, potent and highly selective c-Met kinase inhibitor (IC50 = 0.42 nM.) with antitumor activity. |
|
V0601 | JNJ-38877605 | 943540-75-8 | JNJ-38877605 (JNJ38877605) is an orally bioavailable small-moleculeinhibitor of c-Met with potential antitumor activity. |
|
V4506 | JNJ-38877618 | 943540-74-7 | OMO-1 (formerly known as JNJ-38877618) is a novel, potent, highly selective and orally bioavailable Met kinase inhibitor with nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant MET (IC50 2 and 3 nM ). |
|
V69319 | LMTK3-IN-1 | 2764850-23-7 | LMTK3-IN-1 (compound C28) is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM), which acts through the ubiquitin-proteasome pathway to degrade LMTK3. |
|
V51198 | Mefatinib dimaleate | 1989592-50-8 | Mefatinib is a potent tyrosine kinase inhibitor (TKI) (antagonist) with anti-tumor effects. |
|
V69312 | Mefatinib free base (Mifanertinib) | 1639014-72-4 | Mefatinib free base is a potent tyrosine kinase inhibitor (TKI) (antagonist) with anti-tumor activity. |
|
V33593 | Merestinib dihydrochloride | 1206801-37-7 | Merestinib dihydrochloride (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. |
|
V69306 | MET kinase-IN-2 | 2101241-90-9 | MET kinase-IN-2 is a specific, orally bioactive MET kinase inhibitor (antagonist) with IC50 of 7.4 nM. |
|
V78747 | MET/PDGFRA-IN-1 | MET/PDGFRA-IN-1 (compound 8c) is an inhibitor (blocker/antagonist) of MET and PDGFRA proteins (IC50 for MET: 36 μM). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
